Summit Therapeutics (SMMT) Amortization of Deferred Charges (2019 - 2023)
Summit Therapeutics (SMMT) posted quarterly Amortization of Deferred Charges of $575000.0 for Q4 2023, up 97.59% year-on-year from $291000.0 in Q4 2022, and up 1.41% on a QoQ basis from $567000.0 in Q3 2023.
Summit Therapeutics (SMMT) Amortization of Deferred Charges (2019 - 2023) Analysis & Trends
Summit Therapeutics (SMMT) has reported Amortization of Deferred Charges for 5 consecutive years, with $575000.0 the latest figure, recorded in Q4 2023.
- Quarterly Amortization of Deferred Charges rose 97.59% year-over-year to $575000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.9 million (up 48.04% YoY) and the FY2023 annual result came in at $1.9 million, up 48.04% from the prior year.
- Amortization of Deferred Charges climbed to $575000.0 in Q4 2023 per SMMT's latest filing, from $567000.0 in the prior quarter.
- Over the last five years, Amortization of Deferred Charges for SMMT reached as high as $575000.0 in Q4 2023 and fell as low as $64000.0 in Q4 2019.
- A 5-year average of $278000.0 and a median of $291000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2021 — Amortization of Deferred Charges jumped 353.85% — and 2022, when it fell 18.24%.
- Year by year, Amortization of Deferred Charges stood at $64000.0 in 2019, then soared by 210.94% to $199000.0 in 2020, then soared by 72.36% to $343000.0 in 2021, then declined by 15.16% to $291000.0 in 2022, then jumped by 97.59% to $575000.0 in 2023.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $575000.0, $567000.0, and $425000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn |
| 10 | Summit Therapeutics | 10.45 Bn | 9.76 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 575,000.00 |
| Dec 31, 2023 | 575,000.00 |
| Sep 30, 2023 | 567,000.00 |
| Sep 30, 2023 | 567,000.00 |
| Jun 30, 2023 | 425,000.00 |
| Jun 30, 2023 | 425,000.00 |
| Mar 31, 2023 | 285,000.00 |
| Mar 31, 2023 | 285,000.00 |
| Dec 31, 2022 | 291,000.00 |
| Dec 31, 2022 | 291,000.00 |
| Sep 30, 2022 | 402,000.00 |
| Sep 30, 2022 | 402,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Jun 30, 2022 | 260,000.00 |
| Mar 31, 2022 | 298,000.00 |
| Mar 31, 2022 | 298,000.00 |
| Dec 31, 2021 | 343,000.00 |
| Dec 31, 2021 | 343,000.00 |
| Sep 30, 2021 | 295,000.00 |
| Sep 30, 2021 | 295,000.00 |